Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center forInternational Blood and Marrow Transplant Research Study

Philippe Armand, Haesook T. Kim, Mei Jie Zhang, Waleska S. Perez, Paola S. Dal Cin, Thomas R. Klumpp, Edmund K. Waller, Mark R. Litzow, Jane L. Liesveld, Hillard M. Lazarus, Andrew S. Artz, Vikas Gupta, Bipin N. Savani, Philip L. McCarthy, Jean Yves Cahn, Harry C. Schouten, Jürgen Finke, Edward D. Ball, Mahmoud D. Aljurf, Corey S. CutlerJacob M. Rowe, Joseph H. Antin, Luis M. Isola, Paolo Di Bartolomeo, Bruce M. Camitta, Alan M. Miller, Mitchell S. Cairo, Keith Stockerl-Goldstein, Jorge Sierra, M. Lynn Savoie, Joerg Halter, Patrick J. Stiff, Chadi Nabhan, Ann A. Jakubowski, Donald W. Bunjes, Effie W. Petersdorf, Steven M. Devine, Richard T. Maziarz, Martin Bornhauser, Victor A. Lewis, David I. Marks, Christopher N. Bredeson, Robert J. Soiffer, Daniel J. Weisdorf

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials.

Original languageEnglish (US)
Pages (from-to)280-288
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number2
DOIs
StatePublished - Feb 2012

Bibliographical note

Funding Information:
Financial disclosure: Philippe Armand is supported by an American Society of Hematology Scholar Award and an American Society of Clinical Oncology Career Development Award. This work was also supported by National Institute of Allergy and Infectious Diseases (NIAID) Grant U19 AI 29530 and National Heart, Lung and Blood Institute (NHLBI) Grant PO1 HL 070149 . The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute, NHLBI, and NIAID ; Grant/Cooperative Agreement 5U01HL069294 from the NHLBI and National Cancer Institute ; Contract HHSH234200637015C with the Health Resources and Services Administration; Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from Allos, Amgen, Angioblast, anonymous donation to the Medical College of Wisconsin, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Buchanan Family Foundation, CaridianBCT, Celgene, CellGenix, Children’s Leukemia Research Association, Fresenius-Biotech North America, Gamida Cell Teva Joint Venture, Genentech, Genzyme, GlaxoSmithKline, Kiadis Pharma, Leukemia and Lymphoma Society, Medical College of Wisconsin, Millennium Pharmaceuticals, Milliman USA, Miltenyi Biotec, National Marrow Donor Program, Optum Healthcare Solutions, Otsuka America Pharmaceutical, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, Swedish Orphan Biovitrum, THERAKOS, and Wellpoint. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.

Keywords

  • AML
  • Karyotype
  • SCT

Fingerprint Dive into the research topics of 'Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center forInternational Blood and Marrow Transplant Research Study'. Together they form a unique fingerprint.

Cite this